Evofem Biosciences, Inc. is a biopharmaceutical company commercializing life-changing sexual and reproductive health drugs.
These include Phexx® (lactic acid, citric acid, and potassium bitartrate), the first and only FDA-approved hormone-free contraceptive vaginal gel, and
SOLOSEC® (secnidazole) 2g oral granules, a single-dose oral treatment for two sexually transmitted infections – trichomoniasis and bacterial vaginosis.
Building on four consecutive years of annual net sales growth in our core U.S. market, we aim to catalyze domestic growth
while diversifying and expanding revenues by entering global markets through license and distribution agreements.
We look forward to the first international launches for Phexx® and SOLOSEC® by our licensee for MENA in 2026.
Founded in 2007 and publicly-traded since 2018, Evofem Biosciences is headquartered in San Diego, California.